Respert: "Ahem" indeed. GSK doesn't resume trading

Respert: "Ahem" indeed. GSK doesn't resume trading in New York until Friday. In the meantime, it has just reduced its share count by 20% through a 4 for 5 reverse split, which represents about $22.5 B in market cap. I freely admit that I don't know what I don't know in such matters, but it appears to my untrained eye that GSK has created a pool of over $20B to use for a merger. And GSK certainly needs to do something to jump start the New GSK. Clearly, Leronlimab is not the only promising new drug out there, but I doubt there are any others with its revenue potential over the next 5 years. Ahem.